<DOC>
	<DOCNO>NCT02343406</DOCNO>
	<brief_summary>This study evaluate efficacy safety ABT-414 alone temozolomide versus temozolomide lomustine alone participant recurrent glioblastoma multiforme . The study include Pediatric sub-study evaluate safety , tolerability pharmacokinetics ABT-414 pediatric population . Adult enrollment complete study recruit pediatric participant .</brief_summary>
	<brief_title>Adult Study : ABT-414 Alone ABT-414 Plus Temozolomide vs. Lomustine Temozolomide Recurrent Glioblastoma Pediatric Study : Evaluation ABT-414 Children With High Grade Gliomas</brief_title>
	<detailed_description>The pediatric sub-study uncontrolled , open-label , single-arm global study . This sub-study evaluate safety , tolerability , pharmacokinetics ABT-414 pediatric population le 18 year age well assess effect ABT-414 tumor response per Response Assessment Neuro-Oncology ( RANO ) criterion .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<criteria>Adult participant ( great equal 18 year old ) : Histologically confirm de novo ( primary ) Glioblastoma Multiforme unequivocal tumor progression recurrence . In case test time first progression : either least 3 month end radiotherapy tumor progression clearly outside radiation field tumor progression unequivocally proven surgery/biopsy Absence psychological , familial , sociological geographical factor potentially hamper compliance study protocol followup schedule ; condition assess patient registration trial . Availability adequate biological material ( formalinfixed paraffin embed [ FFPE ] tumor ) central test Epithelial Growth Factor Receptor ( EGFR ) amplification Presence EGFR amplification confirm central assessment ; participant undetermined EGFR status exclude World Health Organization ( WHO ) Performance status 0 2 No one line chemotherapy ( concurrent adjuvant Temozolomide base chemotherapy include combination another investigational agent consider one line chemotherapy ) . Chemotherapy must complete least 4 week prior randomization . Post surgery MRI within 48 hour follow surgery , however MRI scan do within 2 week prior randomization . Surgery complete least 2 week randomization patient fully recover assessed investigator . Pediatric substudy participant ( less 18 year old ) : Histologically proven high grade glioma ( HGG : WHO grade III glioma [ e.g anaplastic astrocytoma , anaplastic oligodendroglioma , anaplastic oligoastrocytoma ] , grade IV glioma [ e.g glioblastoma , gliosarcoma ] diffuse intrinsic pontine glioma [ DIPG ] ) . Must either recurrent/progressive tumor , newly diagnose , complete planned radiation therapy least 4 week prior first dose ABT414 . The tumor tissue must determine EGFR amplification , perform either local central laboratory . If EGFR amplification identify local laboratory , result central confirmation EGFR amplification necessary enrollment patient study . Participant sufficiently recover previous therapy . Adult population ( great equal 18 year old ) : Prior treatment nitrosoureas Prior treatment bevacizumab Previous exposure Epithelial Growth Factor Receptor ( EGFR ) target agent , include EGFRvIII target agent Prior discontinuation temozolomide chemotherapy toxicity reason Prior Radiation Therapy ( RT ) dose 65 Gy , stereotactic radiosurgery brachytherapy unless recurrence histologically proven Previous malignancy , except previous malignancy treat curative intent 5 year prior randomization , except adequately control limited basal cell carcinoma skin , squamous carcinoma skin carcinoma situ cervix Women childbearing potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior randomization . No history wheat allergy Coeliac disease . No EIAED , patient require anticonvulsant therapy must take nonenzyme induce antiepileptic drug ( nonEIAED ) . Patients previously EIAED must fully switch nonEIAED least 2 week prior randomization . Pediatric substudy ( less 18 year old ) : ( For recurrent disease ) No prior RT dose 65Gy brain , stereotactic radiosurgery brachytherapy unless recurrence histologically proven No current recent ( within 4 week 5 halflives ( whichever short ) enrollment ) treatment another investigational drug Female participant childbearing potential must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 72 hour prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>European Organization Research Treatment Cancer</keyword>
	<keyword>Brain Tumor Group</keyword>
	<keyword>Lomustine</keyword>
	<keyword>Pediatric High Grade Gliomas</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Pediatric diffuse Intrinsic Pontine Glioma</keyword>
	<keyword>Children</keyword>
	<keyword>Epithelial Growth Factor vIII mutation</keyword>
	<keyword>Antibody Drug Conjugate</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>recurrent glioblastoma</keyword>
	<keyword>Epithelial Growth Factor</keyword>
	<keyword>ABT-414</keyword>
	<keyword>EORTC</keyword>
	<keyword>Pediatric WHO grade III glioma</keyword>
	<keyword>EGFR amplification</keyword>
	<keyword>Pediatric WHO grade IV glioma</keyword>
	<keyword>Brain Tumor</keyword>
</DOC>